Home › Research › Biomarkers
Efficacy of Ginkgo biloba as an adjunct to donepezil in amyloid PET-positive Alzheimer's patients
Yang Y, Koo MS, Kwak YT.. Frontiers in neurology, 2025-03-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Ginkgo biloba is widely used in some regions as an adjunct therapy for Alzheimer's disease (AD). Its potential mechanisms include antioxidative and anti-amyloid properties, yet clinical evidence remains mixed. Objective We investigated whether combining Ginkgo with donepezil confers additional benefits in amyloid PET-positive AD patients. We also explored changes in the plasma biomarker MDS-Oaβ (Multimer Detection System-Oligomeric Aβ), which reflects the propensity of Aβ monomers to form oligomers. Methods This retrospective study included newly diagnosed, drug-naïve AD patients who were amyloid PET-positive and had at least 12 months of follow-up. Participants received either donepezil alone (Donepezil-only) or donepezil plus Ginkgo (Donepezil-Ginkgo). Clinical measures included the Korean version of the Mini-Mental State Examination (K-MMSE) and the Sum of Boxes of the Clinical Dementia Rating (CDR-SB). Plasma MDS-Oaβ was assessed at baseline and at 12 months. Results A total of 101 patients were analyzed (60 Donepezil-only, 41 Donepezil-Ginkgo). Baseline demographics and clinical characteristics were similar. After 12 months, the Donepezil-only group showed minimal change in K-MMSE and a slight decrease in MDS-Oaβ. The Donepezil-Ginkgo group demonstrated a significant improvement in K-MMSE (+2.4) and a larger reduction in MDS-Oaβ (-0.15). No significant between-group difference was observed for CDR-SB. Adverse events were mostly mild and did not lead to discontinuation. Conclusion The addition of Ginkgo to donepezil may yield superior cognitive outcomes and a greater decrease in plasma MDS-Oaβ compared with donepezil alone in amyloid PET-positive AD patients. Further large-scale, prospective trials are warranted to validate these findings and elucidate Ginkgo's mechanistic role in AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yang, Y., Koo, M. S., & Kwak, Y. T. (2025). Efficacy of Ginkgo biloba as an adjunct to donepezil in amyloid PET-positive Alzheimer's patients. Frontiers in neurology. https://doi.org/10.3389/fneur.2025.1563056
Vancouver
Yang Y, Koo MS, Kwak YT. Efficacy of Ginkgo biloba as an adjunct to donepezil in amyloid PET-positive Alzheimer's patients. Frontiers in neurology. 2025. doi:10.3389/fneur.2025.1563056. PMID: 40134691.
BibTeX
@article{yang2025-40134691,
author = {Yang, Y. and Koo, M. S. and Kwak, Y. T.},
title = {{Efficacy of Ginkgo biloba as an adjunct to donepezil in amyloid PET-positive Alzheimer's patients}},
journal = {Frontiers in neurology},
year = {2025},
doi = {10.3389/fneur.2025.1563056},
pmid = {40134691},
url = {https://doi.org/10.3389/fneur.2025.1563056}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results A total of 101 patients were analyzed (60 Donepezil-only, 41 Donepezil-Ginkgo).
- The Donepezil-Ginkgo group demonstrated a significant improvement in K-MMSE (+2.4) and a larger reduction in MDS-Oaβ (-0.15).
- No significant between-group difference was observed for CDR-SB.
- Conclusion The addition of Ginkgo to donepezil may yield superior cognitive outcomes and a greater decrease in plasma MDS-Oaβ compared with donepezil alone in amyloid PET-positive AD patients.
- Further large-scale, prospective trials are warranted to validate these findings and elucidate Ginkgo's mechanistic role in AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants101
- Evidence strengthLow
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 31 of the 58 points we could judge it on, which is 53 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 101 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40134691) |
| Free to read | 2 / 2 | Free to read |
| Points | 31 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 31 of the 58 points we could judge it on is 53 out of 100. |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “ginkgo-biloba”
2 studies in the library carry the topic tag “ginkgo-biloba”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.